Zacks Investment Research lowered shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a sell rating in a research report released on Monday.

According to Zacks, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. “

A number of other equities research analysts have also recently weighed in on the company. Stephens cut Fate Therapeutics from an overweight rating to an equal rating in a research note on Thursday, January 3rd. BidaskClub cut Fate Therapeutics from a strong-buy rating to a buy rating in a research note on Thursday, December 20th. Jefferies Financial Group assumed coverage on Fate Therapeutics in a research note on Monday, November 5th. They issued a buy rating and a $17.00 price objective for the company. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $23.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, September 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Fate Therapeutics has an average rating of Buy and a consensus target price of $17.25.

NASDAQ FATE traded down $0.47 on Monday, reaching $17.12. The stock had a trading volume of 13,102 shares, compared to its average volume of 905,309. The company has a current ratio of 9.44, a quick ratio of 9.44 and a debt-to-equity ratio of 0.07. Fate Therapeutics has a 12-month low of $6.50 and a 12-month high of $17.98. The stock has a market cap of $1.12 billion, a P/E ratio of -16.85 and a beta of 2.03.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.06). Fate Therapeutics had a negative net margin of 1,536.05% and a negative return on equity of 68.57%. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.24 million. During the same quarter in the prior year, the firm posted ($0.26) EPS. Fate Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. As a group, research analysts predict that Fate Therapeutics will post -1.21 earnings per share for the current year.

In other news, General Counsel Cindy Tahl sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, January 7th. The stock was sold at an average price of $16.00, for a total transaction of $400,000.00. Following the completion of the sale, the general counsel now owns 47,426 shares in the company, valued at $758,816. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amir Nashat sold 82,528 shares of the company’s stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $16.71, for a total value of $1,379,042.88. The disclosure for this sale can be found here. Insiders have sold 216,526 shares of company stock valued at $3,297,783 in the last 90 days. Company insiders own 9.89% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in FATE. Redmile Group LLC raised its position in Fate Therapeutics by 58.9% in the third quarter. Redmile Group LLC now owns 10,576,363 shares of the biopharmaceutical company’s stock worth $172,289,000 after acquiring an additional 3,920,401 shares in the last quarter. FMR LLC raised its position in Fate Therapeutics by 15.3% in the third quarter. FMR LLC now owns 7,637,402 shares of the biopharmaceutical company’s stock worth $124,413,000 after acquiring an additional 1,011,596 shares in the last quarter. BlackRock Inc. raised its position in Fate Therapeutics by 5.6% in the third quarter. BlackRock Inc. now owns 3,469,531 shares of the biopharmaceutical company’s stock worth $56,519,000 after acquiring an additional 183,701 shares in the last quarter. Vanguard Group Inc. raised its position in Fate Therapeutics by 12.7% in the third quarter. Vanguard Group Inc. now owns 2,448,279 shares of the biopharmaceutical company’s stock worth $39,882,000 after acquiring an additional 275,828 shares in the last quarter. Finally, Vanguard Group Inc raised its position in Fate Therapeutics by 12.7% in the third quarter. Vanguard Group Inc now owns 2,448,279 shares of the biopharmaceutical company’s stock worth $39,882,000 after acquiring an additional 275,828 shares in the last quarter. Institutional investors and hedge funds own 84.85% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.

Read More: Consumer behavior in bull markets

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.